

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauUSAN 11/501,464
For IDS filed 11/10/06

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 207/04, 211/32, 223/02, 225/02, 401/12, 413/12, A61K 31/33, 31/40, 31/41, 31/42, 31/47, 31/553, 31/445	A1	(11) International Publication Number: WO 96/18615 (43) International Publication Date: 20 June 1996 (20.06.96)
(21) International Application Number: PCT/US95/15364 (22) International Filing Date: 29 November 1995 (29.11.95) (30) Priority Data: 08/357,481 16 December 1994 (16.12.94) US (71) Applicant (for all designated States except US): RHONE-POULENC RORER PHARMACEUTICALS INC. [US/US]; 500 Arcola Road, P.O. Box 1200, M.S. 3C43, Collegeville, PA 19426-0107 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PAULS, Henry, W. [CA/US]; 3770 Worthington Circle, Collegeville, PA 19426 (US). CHOI, Yong-Mi [US/US]; 340D Willowbrook Drive, Jeffersonville, PA 19403 (US). STUDDT, Robert, W. [US/US]; 38-5 Cranberry Ridge, Reading, PA 19606 (US). MAGUIRE, Martin, P. [US/US]; 603 Meadowview Lane, Mont Clare, PA 19453 (US). SPADA, Alfred, P. [US/US]; 473 Painter Way, Lansdale, PA 19446 (US). CHA, Don, D. [US/US]; 4026 Killington Court, Eagleville, PA 19408 (US).	(74) Agents: NICHOLSON, James, A. et al.; Rhône-Poulenc Rorer Inc., 500 Arcola Road, P.O. Box 1200, M.S. 3C43, Collegeville, PA 19426-0107 (US). (81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i>	
(54) Title: POLYARYLCARBAMOYLAZA -AND- CARBAMOYLALKANEDIOIC ACIDS		
(57) Abstract This invention relates to a class of novel dicarboxy amide derivatives of lipophilic amines which exhibit squalene synthase inhibition properties. More specifically the compounds are bis-aryl and/or heteroaryl alkyl or cycloalkylamino dicarboxy amides. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

1

POLYARYLCARBAMOYLaza -and-
CARBAMOYLALKANEDIOIC ACIDS

10

Field of the Invention

15 The present invention relates to a class of novel compounds useful in the treatment of diseases associated with undesirably elevated cholesterol levels in the body, and particularly diseases of the cardiovascular system, such as atherosclerosis. Compounds of the present invention may also be useful in treating fungal infections.

20 Only about 7% of the total body cholesterol is present in the plasma, where it has been linked to atherosclerosis. The remaining 93% is located in cells, where it performs vital structural and metabolic functions. Excluding the diet, which accounts for approximately one-third of the total body cholesterol, the cells obtain the necessary cholesterol by endogenous biosynthesis (Figure
25 1) or by uptake of low density lipoprotein (LDL) from the bloodstream. Various approaches to the control of plasma cholesterol levels have been pursued. However, it has been shown that inhibiting endogenous cholesterol biosynthesis results in uncreased LDL uptake by cells to satisfy their cholesterol requirements. Increased LDL uptake by cells, especially liver cells, has been
30 shown to lower plasma cholesterol levels.

Squalene synthase is a microsomal enzyme that catalyzes the reductive dimerization of two molecules of farnesyl diphosphate to form squalene. While farnesyl diphosphate serves as the precursor to several other biologically
35 important compounds, squalene is utilized only for cholesterol biosynthesis. Consequently, this is the first totally committed step in the biosynthesis of cholesterol (see Figure 1). Inhibition at this step would stop only *de novo*

cholesterol synthesis while allowing other essential pathways to isopentenyl tRNA, the prenylated proteins, ubiquinone, and dolichol to proceed unimpeded.

5 Inhibition of HMG-CoA reductase, an enzyme positioned early in the cholesterol biosynthetic pathway, results in a decrease of *de novo* cholesterol biosynthesis and an accompanying up-regulation of LDL receptors. However due to a large induction in the amount of the HMG-CoA reductase enzyme, the effect of this inhibition is blunted somewhat and the maximum LDL cholesterol reductions attainable are limited. Since inhibition of squalene synthase does not
10 cause the same amount of enzyme induction (HMG-CoA reductase or squalene synthase), its inhibition results in a greater reduction of *de novo* cholesterol biosynthesis. This translates into more up-regulation of LDL receptors than is seen with an HMG-CoA reductase inhibitor and greater efficacy for lowering circulating LDL levels.

15

Reported Developments

The literature describes the cholesterol biosynthetic pathway and possible means for the inhibition of squalene synthase. In a series of papers
20 including *J. Am. Chem. Soc.* **104**, 7376-7378 (1982) and *J. Am. Chem. Soc.* **111**, 3734-3739 (1989), C. Dale Poulter, et al disclose that ammonium substituted cyclopropyl polyene compounds mimic the topological and electrostatic properties of the primary cation and tertiary cation of presqualene diphosphate. and in the presence of phosphate buffer, inhibit squalene
25 synthase. Scott A. Biller et al, *J. Med. Chem.* **31**, 1869-1871 (1988), disclose that a series of stable, non-ionizable analogues of farnesyl diphosphate, comprising phosphomethylene phosphate polyene compounds, inhibit squalene synthase.

30 Paul E. Schurr and Charles E. Day, *Lipids*, **12**, 22-28 (19), describe a compound known as U-41,792, 1-[p-(1-adamantyloxy)phenyl]-piperidine, which is stated to cause a reduction in lower density lipoproteins, and is designated by the authors as having hypobetalipoproteinemia activity

35 International Patent Application published under the Patent Cooperation Treaty having International Publication Number WO 92/15579 is directed to multicyclic tertiary amine polyaromatic squalene synthase inhibitors containing a

multiazacyclic ring. United States Serial No. 07/997,818, filed December 29, 1992 is directed to cycloalkyl amine bis-aryl squalene synthase inhibitors.

United States Serial No. 08/65,966 is directed to aliphatic amino bis-aryl squalene synthase inhibitors. International Patent Application Number

- 5 PCT/US93/12638, filed December 29, 1993, is directed to cycloalkyl amine bis-aryl squalene synthase inhibitors. United States Serial No. 08/083,117, filed June 25, 1993, is directed to amino bi- and tri-carboxylic alkane bis-aryl squalene synthase inhibitors. Each of these applications is assigned to the same assignee as the present application.

10

European Patent Application 94102059.6, filed February 10, 1994 having Publication Number 0611749A1, assigned to Banyu Pharmaceutical Co., Ltd., is directed to substituted amic acid derivatives which are squalene synthase inhibitors.

15

United States Patent 5,135,935 assigned to Merck and Co., is directed to squalene synthase inhibitors which are aryl-oxadiazole-quinuclidines.

- International Patent Applications published under the Patent Cooperation Treaty having International Publication Numbers: WO 92/12159, 92/12158, 92/12157, 20 92/12156 92/12160 and 92/15579 and being assigned to Glaxo Group Ltd. and United States Patents 5,278,320 and 5,258,401, Great Britain Patent 2,275,470-A, and European Patent Applications 450,812 A1, 512,865 A2 and 526,936 A2 and being assigned to Merck & co. Inc. are directed to bridged cyclic ketal derivatives for lowering the level of blood plasma cholesterol. Further, PCT 25 Patent Application having Document Number WO9418157-A1 is directed to viridifungins which are squalene synthase inhibitors.


- Patent Cooperation Treaty Publication Numbers: WO 93/09115 and WO 93/13096, both of which are assigned to Imperial Chemical Industries PLC, and 30 WO 93/21184, WO 93/21183, WO 93/24486, WO 94/03451, WO 94/14803, WO 94/14804 and WO 94/14805, assigned to Zeneca Limited, are all directed to quinuclidinyl-containing squalene synthase inhibitors.

Summary of the Invention

35

The present invention is directed to a class of novel polyarylcabamoyl-
aza and cabamoylalkanedioic acids which exhibit squalene synthase inhibition
properties.

- 5 More specifically, this invention comprises a class of chemical
compounds described as bis-aryl and/or heteroaryl alkyl or cycloalkyl
cabamoylaza and cabamoylalkanedioic acids. The compounds of this
invention may be described by general formula I.



10



Formula I

where:


A is O, S, NR, SO, SO₂ or a bond;

15

B is (CRR)₁₋₂, O, S, NR, SO, SO₂, RC=CR, C≡C, O=C or a bond;



20



W is a bond, (CRR)_h, or NR;

25

R is independently hydrogen or alkyl;

R' and R" are independently hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl or phenyl;

5 R' and R" together may form a double bond;

R₁ and R₂ are independently hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl or phenyl;

10 R₃, R₄, R₅ and R₆ are independently hydrogen, or alkyl;

R₇ is H, NRR or OH and when W is (CRR)_h then R₇ is OH;

one of R₃, R₄, R₅, R₆ or R₇ is OH;

15 Alk is bi- or tri- carbocycloalkane;

Ar I and Ar II are independently a mono- or di-aryl or heteroaryl;

20 a and b are independently 0-3;

a + b is 0-4;

d is 0-3;

25 a + b + d is 1-3;

e is 0-3;

f is 0-2;

30 g is 0-2;

h is 1-2

35 m and n are independently 0-2;

x is 1-6;

y is 0-2;

x + y is 3-6; and

5

its stereoisomers, enantiomers, diastereoisomers and racemic mixtures; or a pharmaceutically acceptable salt thereof.

10

Description of the Drawing

Figure 1 is a schematic diagram of the biosynthetic pathway of cholesterol.

15

Detailed Description and Preferred Embodiments

As employed above and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

20

"Aryl" means a monocyclic or bicyclic carbocyclic or heterocyclic aromatic ring.

25

"Mono-aryl or heteroaryl" means a monocyclic carbocyclic or heterocyclic aromatic ring. Preferred rings are substituted or unsubstituted pyrrole, thiophene, furan, imidazole, pyrazole, 1,2,4-triazole, pyridine, pyrazine, pyrimidine, pyridazine, thiazole, isothiazole, oxazole, isoxazole, s-triazine and benzene. Preferred groups include phenyl, pyridyl, thienyl, pyridinyl, furyl and pyrimidinyl.

30

"Di-aryl or heteroaryl" means a bicyclic ring system composed of two fused carbocyclic and/or heterocyclic aromatic rings. Preferred bicyclic rings include substituted and unsubstituted indene, isoindene, benzofuran, dihydrobenzofuran, benzothiophene, indole, 1H-indazole, indoline, azulene, tetrahydroazulene, benzopyrazole, benzoimidazole, benzoxazole, benzothiazole, 1,3-benzodioxole, 1,4-benzodioxan, purine, naphthalene, tetralin, coumarin, chromone, chromene, 1,2-dihydrobenzothiopyran, tetrahydrobenzothiopyran, quinoline, isoquinoline, quinazoline, pyrido[3,4-b]-pyridine, and 1,4-

35

benzisoxazine. Preferred groups include naphthyl, benzoxazolyl, indolyl, benzothienyl, benzofuranyl, quinolinyl and benzothiazolyl.

"Alkyl" means a saturated aliphatic hydrocarbon, either branched- or straight-chained. Preferred alkyl is "lower alkyl" having about 1 to about 6 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, t-butyl, amyl and hexyl.

"Aralkyl" means an aryl group bonded to an alkyl group of about 1 to 6 carbon atoms. The preferred "aralkyl" groups are benzyl and phenethyl.


"Alkoxy" means an alkyl-O-group.

"Aryloxy" means an aryl-O-group.


"Halo" means a halogen. Preferred halogens include chloride, bromide and fluoride.

The preferred haloalkyl group is mono, di or trifluoromethyl.


The more preferred compounds of this invention are described by formulae IIa-Vb:




Formula IIa



Formula IIb




Formula IIIa




Formula IIIb

5




Formula IVa




Formula IVb

10




Formula Va

15




Formula Vb


The most preferred compounds of this invention are described by
 5 Formulae VI-VIII:



Formula VI



Formula VII




Formula VIII

15


where Ar II is phenyl, naphthyl, quinolinyl, benzoxazolyl or benzthiazolyl.

Of particular importance are compounds described by formulae IX-XIII.




Formula IX


20




Formula X



Formula XI




Formula XII



Formula XIII


A special embodiment of this invention includes those compounds of

15 **Formula XIV:**



Formula XIV

20 and in particular the compounds of Formula XV:




Formula XV

The compounds of the present invention may be prepared by the following general methods.


Step A1




Step A2



Step B1



Step B2



In general the first step (A1) involves coupling of a dialkyl citrate with a lipophilic amine in the presence of a condensation reagent like those described for the synthesis of amide bonds. The primary or secondary amine starting material are in some cases commercially available but more often are prepared by methods described herein or in copending application Nos. 08/065,966, 08/083,117 and PCT/US93/12638. The dialkylcitrates are prepared from the citrate triesters by treatment with one equivalent of a strong base followed by chromatographic isolation of the monoacid.

The dicarboxybutanoyl derivatives can be prepared by treating a starting amine with one equivalent of the dialkyl citric acid such as 1-(3-dimethyl-aminopropyl)3-ethylcarbodiimide hydrochloride (EDC), 0.5-1.0 equivalent of
5 hydroxybenztriazole (HOBt) and two equivalents of a tertiary amine like triethyl amine in a polar aprotic solvent preferably tetrahydrofuran (THF) at room temperature under argon overnight. The reaction is worked up by any one of a number of standard extractive methods. For example, the reaction mixture is concentrated to dryness and diluted with a polar solvent such as methylene
10 chloride. A basic extractive workup followed by flash chromatography provides the pure product. Alternatively the reaction mixture is diluted with ethyl acetate washed successively with dil. hydrochloric acid and sat. bicarbonate then chromatographed as above.

15 The dicarboxylic acids are generally obtained from the diethyl esters by standard hydrolysis conditions as shown in Step B1. A solution of the diester in ethanol or ethanol/THF is treated with a strong inorganic base such as 10N sodium hydroxide, preferably three-four molar equivalents, at room temperature under argon overnight. (If after several hours a precipitate forms, a few milliliters
20 of water is added to the reaction mixture until the solution is homogeneous again). After stirring a total of 24-48 hours, a precipitate may form. In such a case the reaction mixture may be further concentrated and the solid collected and washed with cold ethanol and/or diethyl ether and the product isolated as the di-sodium salt.

25

Alternatively, the solid may be dissolved in water and acidified to pH<4. If
a solid is formed, it is filtered and washed several times with water then dried under vacuum to yield the free diacid. The product may be further purified if
necessary using high pressure liquid chromatography (HPLC). If the free acid is
30 water soluble, the aqueous solution is concentrated and the product is isolated by HPLC.

In general, the ureas can be prepared by standard coupling methods as shown in Step A2. A solution of the amine in an organic solvent preferably
35 methylene chloride (CH_2Cl_2) is treated with phosgene or its equivalent, preferably triphosgene (1/3 equivalents) and excess tertiary amine, preferably 3.5 fold excess of triethylamine, at room temperature under argon for several

hours, preferably five hours. The reaction mixture is subsequently treated with one equivalent of 2-aminobutandioic acid dimethyl ester. If a hydrochloride salt is used a slight excess of tertiary amine, preferably 1.1 fold excess of triethylamine is added. The reaction mixture is heated to 30-40 °C preferably 40 °C overnight. An extractive workup followed by flash chromatography yields the product.

The urea derivatives are generally obtained by treating the diester (step B2) with an excess of a strong inorganic base such as lithium hydroxide hydrate preferably ten equivalents in THF/methanol/water (3:1:1 v/v/v) at room temperature overnight. The reaction mixture is evaporated to near dryness then dissolved in hot water. The aqueous solution is washed with an organic solvent such as diethyl ether then acidified with concentrated HCl until the pH is ca. 1-3, but preferably 2. Upon precipitation of a white solid the suspension is placed in the refrigerator for about 30 min. The solid is collected and then dried on the vacuum pump. If no product precipitates the water is removed under vacuum and the product is isolated by HPLC.

Certain compounds of this invention may have at least one asymmetric carbon atom. Further, certain compounds of this invention may exist in their cis or trans configuration. As a result, those compounds of this invention may be obtained either as racemic mixtures, diastereoisomeric mixtures or as individual enantiomers. When two or three asymmetric centers are present the product may exist as mixtures of two or four diastereomers. Of course it is understood that certain other compounds within the scope of this invention could have a number of stereocenters. In general, a compound with x stereocenters can have a maximum of 2^x stereoisomers. Therefore, a compound having three such centers gives rise to a maximum of eight stereoisomers, while one having four produces sixteen, etc. The product may be synthesized as a mixture of the isomers and then the desired isomer separated by conventional techniques such as chromatography or fractional crystallization from which each diastereomer may be resolved. On the other hand, synthesis may be carried out by known stereospecific processes using the desired form of the intermediate which would result in obtaining the desired stereospecificity. In general, the compounds of this invention are prepared as mixtures of stereoisomers, containing less than the maximum number of stereoisomers for a given number of stereocenters.

Reference to the separation of cis and trans isomers by chromatography may be found in W.K. Chan, et al, *J. Am. Chem. Soc.* **96**, 3642 (1974).

5 It is to be understood that the scope of this invention encompasses not only the various isomers which may exist but also the various mixture of isomers which may be formed.

The resolution of the compounds of this invention and their starting materials may be carried out by known procedures. Incorporation by reference
10 is hereby made to the four volume compendium *Optical Resolution Procedures for Chemical Compounds*: Optical Resolution Information Center, Manhattan College, Riverdale, New York. Such procedures are useful in the practice of this invention. A further useful reference is *Enantiomers, Racemates and Resolutions*: Jean Jacques, Andre Collet and Samuel H. Wilen; John Wiley &
15 Sons, Inc., New York, 1981. Basically, the resolution of the compounds is based on the differences in the physical properties of diastereomers. Conversion of the racemates into a mixture of diastereomers by attachment of an enantiomerically pure moiety results in forms that are separable by fractional crystallization, distillation or chromatography.

20

The present compounds form salts with acids when a basic amino function is present and salts with bases when an acid function, i.e., carboxyl, is present. All such salts are useful in the isolation and/or purification of the new products. Of particular value are the pharmaceutically acceptable salts with
25 both acids and bases. Suitable acids include, for example, hydrochloric, oxalic, sulfuric, nitric, benzenesulfonic, toluenesulfonic, acetic, maleic, tartaric and the like which are pharmaceutically acceptable. Basic salts for pharmaceutical use are the Na, K, Ca and Mg salts.

30 Various substituents on the present new compounds can be present in the starting compounds, added to any one of the intermediates or added after formation of the final products by known methods of substitution or conversion reactions. If the substituents themselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety
35 of protecting groups known in the art, may be employed. Examples of many of these possible groups may be found in "*Protective Groups in Organic Synthesis*" by T.W. Green, John Wiley and Sons, 1981. For example, nitro groups can be

added by nitration and the nitro group converted to other groups, such as amino by reduction, and halo by diazotization of the amino group and replacement of the diazo group. Acyl groups can be added by Friedel-Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction. Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers. Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product.

Since the compounds of this invention have certain substituents which are necessarily present, the introduction of each substituent is, of course, dependent on the specific substituents involved and the chemistry necessary for their formation. Thus, consideration of how one substituent would be affected by a chemical reaction when forming a second substituent would involve techniques familiar to the skilled artisan. This would further be dependent on the ring involved.

The starting amines, reagents and the protected citrate (3-Hydroxy-3,4-bis(ethoxycarbonyl)butanoic acid) used for the preparation of the compounds of the present invention may be obtained by the following representative preparations.

Preparation 1

3-Hydroxy-3,4-bis(ethoxycarbonyl)butanoic acid

A solution of triethyl citrate (34.1 g, 123 mmol) in ethanol and water (30 ml) is treated with sodium hydroxide (3.70 g, 92.6 mmol) and stirred at room temperature under argon for 4.5 hours. The reaction mixture is concentrated on a rotary evaporator then diluted with water (50 ml). The pH is adjusted to ca. 1 using 2 N HCl. The aqueous solution is then extracted with a large excess of chloroform (4 X 150 ml). The combined organic layers are dried (MgSO₄), filtered and concentrated to give crude oil. Purification by flash chromatography (5% MeOH/CH₂Cl₂ to 1% AcOH/5%MeOH/CH₂Cl₂) gives 8.72 g of product (38 %) as a racemate.

^1H NMR (300 MHz, CDCl_3) δ 1.26 (t, 3H, $J = 9$ Hz), 1.31 (t, 3H, $J = 3$ Hz), 2.88 (m, 4H), 4.16 (q, 2H, $J = 2$ Hz), 4.30 (q, 2H,

Preparation 2

5 3-[4-(Benzoxazol-2-yl)benzyloxy]piperidine

3-Hydroxypiperidine hydrochloride (2.5 g, 18.2 mmol) is treated with di-*tert*-butyldicarbonate (4.16 g, 19.06 mmol) and 4-methylmorpholine (4.2 ml, 38.2 mmol) in anhydrous methylene chloride (50 ml) overnight at room temperature. The reaction mixture is diluted with methylene chloride (250 ml) and washed
10 with 5% hydrochloric acid and saturated bicarbonate solution. The organic layer is dried (Na_2SO_4) and concentrated and used without further purification.

A portion of *N-tert*-butoxycarbonyl-3-hydroxypiperidine (0.923 g, 4.6 mmol) so obtained is dissolved in anhydrous tetrahydrofuran (75 ml) and
15 treated with sodium hydride (0.275 g, 60%, 6.88 mmol), previously washed with anhydrous hexane (2 X). The resulting suspension is stirred at room temperature for one hour then treated with 4-(benzoxazol-2-yl)benzyl bromide (1.32 g, 4.6 mmol) and a catalytic amount of tetrabutyl ammonium bromide (0.05 g). Stirring is continued for 20 hours at room temperature and the reaction is
20 quenched with aqueous ammonium chloride. The reaction mixture is diluted with methylene chloride (250 ml) and separated. The aqueous layer is washed with ethyl acetate; the organics are combined and concentrated. The residue is chromatographed (20 % ethyl acetate/hexane) to give the intermediate carbamate (1.0 g).

25

A portion of the carbamate (0.52 g, 1.27 mmol) is dissolved in a solution of 10 % trifluoroacetic acid in anhydrous methylene chloride (10 ml). The solution is stirred overnight at room temperature, diluted with ether and concentrated to about 15 ml. The solid that precipitated is collected as the
30 trifluoroacetate salt of the title compound (0.50 g, 51 % two steps).

MS (EI +ion) m/z 408 M^+

^1H NMR (CDCl_3 , 300 MHz): δ 1.7-2.0 (m, 3H), 2.03-2.20 (m, 1H), 3.2 (m, 3H), 3.25 (m, 1H), 3.7 (m, 1H), 4.65 (s, 2H), 7.35 (m, 2H), 7.5 (d, 2H, $J = 7.9$ Hz) 7.58 (m, 1H), 7.77 (m, 1H), 8.25 (d, 2H).

35

In a like manner by the methods described in preparation 2 the following amines are prepared:

Preparation 33-[4-(Benzoxazol-2-yl)benzyloxymethyl]piperidine

¹H NMR (300 MHz, CDCl₃) δ 1.19 (1 H, m), 1.68 (1 H, m), 1.63-1.65 (4 H, m),
5 2.41 (1 H, m), 2.58 (1 H, m), 3.01 (1 H, m), 3.19 (1 H, m), 3.36 (2 H, m), 4.57 (2
H, s), 7.36 (2 H, m), 7.48 (2 H, d, J = 8.1 Hz), 7.59 (1 H, m), 7.78 (1 H, m), 8.24
(2 H, d J = 8.1 Hz).

Anal. calcd. for C₂₀H₂₂N₂O₂·1.00H₂O: C, 70.57; H, 7.11; N, 8.23.

10 Found: C, 70.60; H, 6.58; N, 8.23.

Preparation 43-[4-(Benzoxazol-2-yl)benzyloxy]pyrrolidine

¹H NMR (300 MHz, CDCl₃) δ 1.93 (3 H, m), 2.88 (2 H, m), 3.12 (2 H, m), 4.15 (1
15 H, m), 4.56 (2 H, br s), 7.36 (2 H, m), 7.50 (2 H, d, J = 8.1 Hz), 7.59 (1 H, m),
7.78 (1 H, m), 8.24 (2 H, br d, J = 8.1 Hz).

Anal. calcd. for C₁₈H₁₈N₂O₂·0.55H₂O: C, 71.05; H, 6.33; N, 9.21.

Found: C, 71.03; H, 6.25; N, 9.07.

20 Preparation 52-(S)-[4-(Benzoxazol-2-yl)benzyloxymethyl]pyrrolidine

A solution of 3.00 g (18.1 mmol) of L-proline methyl ester hydrochloride,
5.05 g (18.1 mmol) of trityl chloride and 10 mL of triethylamine in 40 mL of 1,2-
dichloroethane is stirred at 22 °C. After a few minutes, a thick precipitate began
25 to form. An additional 20 mL of 1,2-dichloroethane is added and the mixture is
heated to 60 °C and stirred for 3 hrs. The reaction mixture is partitioned
between water (100 mL) and CH₂Cl₂ (100 mL). The organic layer is washed
with satd. NaHCO₃ (50 mL), dried (MgSO₄) and evaporated. The residue is
recrystallized from hexane/EtOAc to give 5.76 g of 1-trityl-pyrrolidine-2-
30 carboxylic acid, methyl ester as a white crystalline solid which is used directly in
the next step.

A solution of 5.00 g (13.4 mmol) of the above ester in 50 mL of diethyl
ether is added dropwise to a mixture of 0.509 g (13.4 mmol) of solid lithium
35 aluminum hydride in 10 mL of ether while stirring under nitrogen. The mixture is
brought to a gentle reflux and an additional 6.7 mL (6.7 mmol) of a 1 M solution
of lithium aluminum hydride in ether is injected by syringe. After refluxing for 2

hrs the reaction is cooled to 22 °C and quenched with 10 mL of methanol. The mixture is partitioned between 100 mL of 0.5 M NaOH and 50 mL of ether and then stirred vigorously for 25 minutes and filtered. The ether layer is separated, washed with brine (30 mL), dried (MgSO₄) and evaporated to give 4.20 g of (1-
5 tritylpyrrolidin-2-yl)methanol as a white foam. By the method described in preparation 2, this material is used to prepare the title compound which is recrystallized from ethyl acetate/hexane.
1H NMR (300 MHz, free base, CDCl₃) δ 1.79 (1 H, m), 2.01 (3 H, m), 3.22 (2 H, t, J = 7.1 Hz), 3.67 (2 H, m), 3.81 (1 H, m), 5.56 (1 h, d, J = 12.4 Hz), 5.61 (1 H,
10 d, J = 12.4 Hz), 7.33 (2 H, m), 7.44 (2 H, d, J = 8.3 Hz), 7.56 (1 H, m), 7.75 (1 H, m), 8.18 (2 H, d, J = 8.3 Hz), 9.10 (1 H, br s).
Anal. calcd. for C₁₉H₂₀N₂O₂·HCl: C, 66.18; H, 6.14; N, 8.12.

Found: C, 66.32; H, 6.18; N, 8.02.

15 Preparation 6

6-α-(4-Styrylphenyl)cyclohex-4-enyl-β-amine

4-Stilbenecarboxyaldehyde (10.4 g, 0.05 mol), β-alanine (0.44 g, 0.005 mmol), nitromethane (4.6 g, 0.075 mmol) and ethanol are combined and heated to reflux for 10 hours. The reaction mixture is filtered and the yellow solid
20 recrystallized from ethanol to give the 4-(2-nitrovinyl)stilbene (9.2 g, 73 %).
Anal. Calc. for C₃₁H₃₅NO₇•0.425 H₂O: C 76.49, H 5.18, N 5.58

Found: C 75.89, H 5.27, N 5.94.

The intermediate 4-(2-nitrovinyl)stilbene (5 g, 19.9 mmol) and excess
25 butadiene in toluene (12 ml) is heated to 140 °C for 20 hrs in a sealed tube. The yellow solid which formed upon cooling is filtered and recrystallized from ethanol to give 3.38 g of 2-α-Nitro-1-β-(4-styrylphenyl)cyclohex-4-ene (56 %).

MS (EI +ion) m/z 305 M⁺

Anal. Calc. for C₃₁H₃₅NO₇•0.425 H₂O: C 78.66, H 6.27, N 4.59

30 Found: C 78.22, H 6.38, N 4.46.

Nickel (II) acetate tetrahydrate (1.91 g, 7.6 mmol) in water (77 ml) is treated in two portions with a solution of sodium borohydride (0.579 g, 15.0 mmol) in 0.1 M aqueous NaOH. After the evolution of gas had ceased the
35 granular suspension is centrifuged and the supernatant liquid decanted. The nickel boride is washed with distilled water and again centrifuged to remove the washings. This process is repeated twice more using water then washed with ethanol and finally isopropanol.

A portion of the nickel boride (1.75 g, mmol) is added to 2- α -nitro-1- β -(4-styrylphenyl)cyclohex-4-ene (0.9 g, 2.97 mmol), in isopropanol (60 ml) under argon. The mixture is heated to reflux and treated with hydrazine hydrate (0.66 g, 13.4 mmol) in isopropanol (15 ml) dropwise, over 20 min. The reaction is monitored by TLC (20% EtOAc/Hexane) during the addition, and cooled to room temperature as soon as all the starting material had been consumed. The reaction mixture is filtered through 'hyflo' and concentrated to dryness. The residue is purified by flash chromatography (4 % MeOH/CH₂Cl₂ on silica gel) to give the title compound (0.47 g, 60 %).

MS (EI+ion) m/z 275 M⁺

¹H NMR (300M Hz, CDCl₃) δ 2.0 (m,1H), 2.25-2.4 (m,3H), 2.6 (m,1H), 3.2(m, 1H), 5.75 (bs,2H), 7.1 (s,2H), 7.28 (m,3H), 7.38 (m,2H), 7.5 (m, 4H).

15 Preparation 7

3-Hydroxy-3-(4-naphth-2-yl-phenyl)piperidine

2-(4-Bromophenyl)naphthalene (9.29 g, 32.8 mmol) is placed in a round bottom flask under argon and dissolved in anhydrous THF (150 mL). The solution is cooled to -78 °C in a dry ice/acetone bath with stirring. A solution of n-butyl lithium (2.0 M, 18.0 ml) is added dropwise and after fifteen minutes 1-benzyl-3-piperidone (8.14 g, 36.08 mmol) in 20 mL of THF is added dropwise with vigorous stirring. After 30 minutes the solution is allowed to warm to room temperature and quenched with saturated ammonium chloride (10 ml). The mixture is diluted with ethyl acetate (500 ml), washed with water and brine. The organic layer is dried over MgSO₄ and concentrated on a rotovap. The crude material is purified by silica gel flash column chromatography using 30% ethyl acetate in hexane as the eluant to yield 6.91 g (48 %) of 1-benzyl-3-hydroxy-3-(4-naphth-2-yl-phenyl)piperidine as a white solid.

This intermediate (393 mg, 1.0 mmol) is dissolved in ethanol (50 mL) and water (20 mL) and 50 mg of Degussa type palladium on carbon (10%) added. The material is placed on a Parr hydrogenator overnight at 55 psi hydrogen. The resulting suspension is filtered through Celite and concentrated by rotovap. The material is purified by flash column chromatography using 10 % methanol in methylene chloride with 1 % triethylamine as the eluant to yield 0.118 g (39 %) of 3-hydroxy-3-(4-naphth-2-ylphenyl)piperidine as a light yellow solid.

MS (EI +ion) m/z 303 M⁺.

^1H NMR 300 MHz (CD_3OD) δ 1.67 (m, 1H), 1.89 (m, 1H), 2.10 (m, 1H), 2.79 (m, 2H), 2.94 (m, 1H), 3.06 (m, 1H), 3.18 (m, 1H), 7.08 (m, 2H), 7.38 (m, 2H), 7.65-7.42 (m, 2H), 7.76 (d, $J=12\text{Hz}$, 2H), 7.89 (m, 2H), 8.08 (s, 1H).

- 5 In a like manner by the methods described in Preparation 7 the following compounds are prepared:

Preparation 8

3-Hydroxy-3-[(4-benzoxazo-2-yl)phenyl]piperidine

- 10 MS (FAB) m/z 295 ($\text{M}+\text{H}$) $^+$.

Anal. Calc. for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2 \cdot 0.275 \text{H}_2\text{O}$: C 72.24, H 6.25, N 9.36.

Found: C 72.29, H 6.22, N 9.34.

Preparation 9

- 15 3-Hydroxy-3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)phenyl]piperidine

MS (EI +ion) m/z 311 M^+ .

Preparation 10

3-Hydroxy-3-[4-(2-methoxyquinolin-6-yl)phenyl]piperidine

- 20 MS (EI +ion) m/z 334 M^+

Anal calc. for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_2 \cdot \text{H}_2\text{O}$: C 72.68, H 6.80, N 8.07

Found: C 72.65, H 6.77, N 8.19.

Preparation 11

- 25 3-Hydroxy-3-[4-(3-methoxyphenyl)phenyl]piperidine

MS (EI+ion): m/z 283 M^+

^1H NMR (300 MHz, CDCl_3) δ 1.65 (m, 1H), 1.85 (m, 3H), 2.6 (m, 1H), 2.9 (bs, 2H), 3.05 (m, 1H), 3.85 (s, 3H), 4.76 (bs, 1H), 6.88 (m, 1H), 7.25 (m, 3H), 7.35 (m, 1H), 7.55 (bs, 4H).

30

Preparation 12

3-Hydroxy-3-(biphen-4-yl)piperidine

MS (EI +ion) m/z 253 M^+

Anal calc. for $\text{C}_{17}\text{H}_{19}\text{NO} \cdot \text{HCl} \cdot 0.2\text{H}_2\text{O}$: C 69.59, H 7.01, N 4.77

35

Found: C 69.60, H 6.88, N 4.76.

Preparation 13

3-hydroxy-3-[4-(2-hydroxynaphth-6-yl)phenyl]piperidine

By the method described in Preparation 7, 3-hydroxy-3-[4-(2-*tert*-butyltrimethylsilyloxynaphthalen-6-yl)phenyl]piperidine is prepared from 4-(2-*tert*-butyltrimethylsilyloxynaphthalen-6-yl)phenylbromide. This material (0.98 g, 2.4 mmol) is suspended in anhydrous tetrahydrofuran (40 ml) and treated with a solution of tetrabutylammonium fluoride (2.2 ml, 1 M) dropwise. The reaction mixture is stirred 48 hrs at room temperature, diluted with methylene chloride (250 ml) and washed with saturated sodium chloride solution containing about 5 % potassium carbonate. The resultant precipitated solid is collected, washed successively with ethyl acetate, a small amount of acetone and diethyl ether to give the title product (0.6 g, 95 %).
MS (EI +ion) m/z 320 (M+H)⁺.

Preparation 1415 3-Hydroxy-3-(4-(2-hydroxyquinolin-6-yl)phenyl)piperidine

By the method described in Preparation 7, 1-benzyl-3-hydroxy-3-(4-(2-methoxyquinolin-6-yl)phenyl)piperidine is prepared from 6-(4-bromophenyl)-2-methoxyquinoline. This material (0.20 g, 0.471 mmol) is placed in a sealed tube under nitrogen with chloroform (5 mL), pyridine (0.02 ml, 0.075 mmol), and trimethylsilyliodide (0.107 ml, 0.754 mmol). The mixture is heated slowly to 55 °C in an oil bath for fifteen hours with stirring. The sealed tube is cooled to 0 °C, opened and the contents diluted with methanol (50 ml). The solution is concentrated to dryness and the crude residue is purified by flash column chromatography using 10 % methanol in methylene chloride to yield of 1-benzyl-3-hydroxy-3-(4-(2-hydroxyquinolin-6-yl)phenyl)piperidine as a yellow solid (0.1 g, 51 %). The debenzylation is carried out as in preparation 1 to yield 3-hydroxy-3-(4-(2-hydroxyquinolin-6-yl)-phenyl)-piperidine.

MS (FAB+ion) m/z 321 (M+H)⁺.

¹H NMR (300 MHz, DMSO-d₆) δ 1.24 (m, 1H), 1.58 (m, 1H), 1.73 (m, 1H), 1.97 (m, 1H), 2.78 (m, 4H), 3.35 (d, 2H, J=15 Hz), 5.38 (m, 1H), 6.52 (d, 1H, J=9 Hz), 7.36 (d, 1H, J=9 Hz), 7.65 (m, 4H), 7.83 (d, 1H, J=9 Hz), 7.95 (d, 2H, J=15 Hz).

Preparation 152-Methyl-2-(4-naphth-2-yl-phenyl)morpholine

35 4-Bromoacetophenone (20.0 g, 100 mmol) is placed in a flask under argon along with zinc iodide (1.6 g, 5 mmol) and trimethylsilyl cyanide (20 ml, 150 mmol). The mixture is stirred for 48 hours and then concentrated to

dryness. The material is then treated by the procedures of Clark *J.Hetero.Chem.* **20**, 1393 (1983), to give 2-(4-bromophenyl)-2-methylmorpholine. This material (2.17 g, 8.51 mmol) is dissolved in methylene chloride (25 ml) and treated with triethylamine (2.37 ml, 17 mmol) and Boc-anhydride (1.95 g, 8.93 mmol). The solution is stirred at 25 °C for three hours and then concentrated to dryness. Flash silica chromatography using 10% ethyl acetate in hexane as eluant yielded 2.4 g of the N-*tert*-butoxycarbonyl-2-(4-bromophenyl)-2-methylmorpholine.

- 10 Naphth-2-yltrimethylstannane (0.617 g, 1.8 mmol, preparation 20) is dissolved in DMF (6 ml) and the above aryl bromide (0.630 g, 1.8 mmol) and tetrakis(triphenylphosphine) Pd(0) (0.102 g, 0.09 mmol) are added. The mixture is heated to 90 °C and stirred under argon for 4 hours. After cooling to room temperature the solution is stirred an additional 24 hours then poured into 10 % ammonium hydroxide (30 ml) and methylene chloride (50 ml). The organic layer is separated and washed with water three times, then brine, and dried (MgSO₄). After concentration the material is purified by flash column chromatography using 10 % ethyl acetate in hexane as eluant to yield 0.224 g of an orange oil. The oil is dissolved in methylene chloride (5 ml) and trifluoroacetic acid (2 ml) is added in portions. The solution is stirred for a total of 48 hours diluted with methylene chloride (50 ml) and saturated sodium bicarbonate (10 ml). The organic layer is washed with water and brine, dried (MgSO₄), and concentrated. Purification by flash column chromatography using 3 % methanol in methylene chloride gave 0.098 g of 2-Methyl-2-(4-naphth-2-ylphenyl)morpholine (18 %).
- 20 ¹H NMR (300 MHz, CDCl₃) δ 1.43 (s, 3H), 2.77 (m, 1H), 3.02 (m, 2H), 3.57 (d, 1H, J=12 Hz), 3.70 (m, 2H), 7.49 (m, 1H), 7.55 (d, 3H, J=8.5 Hz), 7.76 (d, 3H), 7.91 (m, 3H), 8.05 (s, 1H).

Preparation 16

30 4-[3-(4-Naphth-2-ylphenyl)]-1,2,5,6-tetrahydropyridine

- 3-Hydroxy-3-(4-naphth-2-yl-phenyl)piperidine (0.10 g, 0.33 mmol) is placed in a flask under argon. Concentrated HBr (5 ml) is added and a water cooled reflux condenser is attached. The solution is heated to reflux with stirring for 15 hours. After cooling to room temperature the mixture is diluted with water and the pH adjusted to 8 with saturated NaHCO₃ solution. The solution is extracted with ethyl acetate (200 ml) and methylene chloride (200 ml). The organic layers are combined, dried (MgSO₄), and concentrated. The material is
- 35

purified by flash chromatography using 10 % methanol in methylene chloride with 1 % triethylamine to yield 0.046 g (49 %) of 4-[3-(4-naphthalen-2-ylphenyl)]-1,2,5,6-tetrahydropyridine as a white solid.

MS (EI +ion) m/z 285 M⁺

- 5 ¹H NMR (300 MHz, CD₃OD) δ 2.37 (m, 2H), 3.04 (m, 2H), 3.76 (m, 2H), 6.43 (m, 1H), 7.49 (m, 4H), 7.76 (m, 3H), 7.91 (m, 3H), 8.10 (s, 1H).

In a like manner by the method described in Preparation 16, the following compound is prepared:

10

Preparation 17

3-[4-(2-Methoxyquinolin-6-yl)phenyl]-1,2,5,6-tetrahydropyridine

MS (EI +ion) m/z 316 M⁺.

- 15 ¹H NMR (300 MHz, CDCl₃) δ 2.33 (s, 2H), 2.56 (m, 2H), 3.30 (m, 2H), 4.01 (br s, 1H), 4.09 (s, 3H), 6.31 (m, 1H), 6.92 (d, 1H), 7.16 (d, 1H, J=6 Hz), 7.40 (d, 1H), 7.65 (d, 1H, J=8.2 Hz), 7.76 (d, 1H, J=7.8 Hz), 7.88 (m, 1H), 8.00 (d, 1H, J=8.8 Hz).

Preparation 18

- 20 2-[4-(1,2,5,6-Tetrahydropyridin-3-yl)phenyl]benzoxazole

A solution of 3-hydroxy-3-(4-benzoxazo-2-ylphenyl)piperidine (0.50 g, 1.7 mmol) and *p*-toluene sulfonic acid in 15 mL of anhydrous toluene is heated to remove toluene. The resulting residue is heated to 160 °C for 0.5 hours. The reaction mixture is cooled to room temperature and dissolved in methylene
25 chloride and washed with 1 N NaOH solution. The organic layer is dried over Na₂SO₄, filtered, concentrated and chromatographed with 5 % to 10 % gradient CH₃OH/CH₂Cl₂ to yield 2-[4-(1,2,5,6-tetrahydropyridin-3-yl)phenyl]benzoxazole (0.376 g, 80 %) as a yellow solid.

MS (EI+ion) m/z 276 M⁺

- 30 Anal calc. for C₁₈H₁₆N₂O•HCl•0.125 H₂O: C 68.62, H 5.52, N 8.89

Found: C 68.39, H 5.42, N 8.76.

Preparation 19

1-Amino-2-(4-bromophenyl)propan-2-ol

- 35 Acetophenone (20.0 g, 0.1 mmol), trimethylsilyl cyanide (20 ml, 0.151 mmol) and zinc iodide (1.6 g, 5 mmol) are combined and stirred under argon for

48 hrs. The reaction is concentrated to a residue which is used without any further purification.

Crude 2-(4-bromophenyl)-2-trimethylsilyloxypropanionitrile from above is added to a 1.0 M solution of lithium aluminum anhydride in THF (0.176 mol) under argon at room temperature. The reaction is stirred for 1h then cooled to 0° C, quenched by the slow dropwise addition of water followed by 10% NaOH solution. The mixture is diluted with CH₂Cl₂ and the organic phase separated. The aqueous phase is extracted three times with CH₂Cl₂ and the combined organic phases are washed with saturated NaCl solution, dried and concentrated to dryness. The product is recrystallized from EtOAc/Hexane to give 13.8 g of 1-amino-2-(4-bromophenyl)propan-2-ol (60 %).

Preparation 20

15 Naphth-2-yltrimethyl stannane

tert-Butyllithium (12.5 ml, 21.25 mmol, 1.7 M in pentane) is added dropwise to a stirred solution of 2-bromonaphthalene (2 g, 9.66 mmol) in anhydrous diethyl ether (40 ml) under argon at -78 °C. The solution is stirred for 15 min and then treated with a 2.71 M solution of trimethyltin chloride in dioxane (4.63 ml, 12.55 mmol). The heterogeneous mixture is warmed to room temperature, diluted with diethyl ether (150 ml) and treated with 10 % NH₄OH solution (90 ml) for 5 minutes. The two phases are separated and the organic phase is washed with water followed by brine, dried over MgSO₄ and concentrated to dryness. The oil is purified by flash silica chromatography (hexane) to give naphthyltrimethyl stannane (2.69 g, 95.6 %).
¹H NMR (300 MHz, CDCl₃) δ 0.2 (s, 9H), 6.78 (m, 3H), 6.89 (d, J=7.8 Hz, 1H), 7.13 (m, 2H), 7.29 (s, 1H).

The compounds of the present invention may be prepared by the following representative examples:

Example 1

4-[3-Hydroxy-3-(4-naphth-2-ylphenyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid

35 3-Hydroxy-3-(4-naphth-2-ylphenyl)piperidine (Preparation 7, 1.24 g, 4.09 mmol), 3-hydroxy-3, 4-bis(ethoxycarbonyl)butanoic acid (Preparation 1, 1.01 g, 4.09 mmol), EDC, (0.785 g, 4.09 mmol), 1-hydroxybenzotriazole (HOBt, 0.055

- g, 2.05 mmol) and triethylamine (570 μ L, 8.18 mmol) in THF or methylene chloride (150 mL) is stirred under argon overnight. The reaction mixture is diluted with CH_2Cl_2 or ethyl acetate and washed with water or 5 % aqueous hydrochloric acid, saturated aqueous sodium bicarbonate, and brine. The organic layer is then dried over MgSO_4 or Na_2SO_4 , filtered and concentrated. The crude product is purified by flash chromatography (using 60 % ethyl acetate in hexane in this instance) to yield the diester intermediate, ethyl 4-[3-hydroxy-3-(4-naphth-2-yl-phenyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-ethoxycarbonylbutanoate (1.63 g, 75 %) as a foam solid.
- Anal. Calc. for $\text{C}_{31}\text{H}_{35}\text{NO}_7 \cdot 0.425 \text{ H}_2\text{O}$: C 68.79, H 6.68, N 2.59
Found: C 68.82, H 6.75, N 2.49.

- The diester intermediate (1.63 g, 3.05 mmol) is dissolved in ethanol (50 mL) and treated with 10 N NaOH (641 μ L, 6.41 mmol). The reaction mixture is stirred at room temperature for 48 hours then optionally heated to 50 $^\circ\text{C}$ for 1 hour. The precipitate which is formed during the reaction is collected, dissolved in water and then filtered. 2 N HCl is added to the aqueous solution until pH=3. A precipitate forms and the crude product is filtered and washed several times with water. The title compound (0.620 g, 43 %) is purified by HPLC (10 mm X 25 cm Dynamax-60A 8 μM C-18 column) ramping from 0-100% acetonitrile in water over 50 min. with a flow rate of 10 mL/min.
- MS (FAB+ion) m/z 478 (M+H)⁺.

- In a like manner by the methods described in Example 1 the following compounds are prepared:

Example 2

4-(N-{2-[4-(Benzoxazol-2-yl)benzyloxy]ethyl}-N-{2-(3-phenylpropoxy)ethyl}carbamoyl)-3-hydroxy-3-carboxybutyric acid

- Anal. Calc. for $\text{C}_{33}\text{H}_{36}\text{N}_2\text{O}_9 \cdot 0.25 \text{ TFA}$: C 63.55, H 5.77, N 4.42

Found: C 63.44 H 5.88, N 4.52.

MS (FAB+ion) m/z 605 (M+H)⁺

Example 3

- 4-[2-Methyl-2-(4-naphthalen-2-yl-phenyl)morpholin-4-ylcarbonyl]3-hydroxy-3-carboxybutanoic acid

From the product of Preparation 15

Anal. Calc. for $C_{27}H_{27}NO_7 \cdot 1.325 H_2O$: C 64.68, H 5.96, N 2.79

Found: C 64.66, H 5.63, N 2.82.

MS (FAB+ion) m/z 478 (M+H)⁺.

5

Example 4

4-[N-(2- α -Hydroxy-3- α -benzyloxycyclohexyl)- β -carbamoyl]-3-hydroxy-3-
10 carboxybutanoic acid

Anal. Calc. for $C_{19}H_{25}NO_8 \cdot 1.225 H_2O$: C 54.66, H 6.63, N 3.36

Found: C 54.69, H 6.50, N 3.35.

MS (FAB+ion) m/z 396 (M+H)⁺.

15 Example 5

4-[2- α -(4-Benzoxazol-2-ylbenzyloxy)cyclohexyl- β -carbamoyl]-3-hydroxy-3-
carboxybutyric acid

The title compound is prepared as described in example 1 except that
solid NaOH (large excess) in ethanol/water (3:1) is used to hydrolyze the ester
20 at room temperature. The title compound is purified by HPLC as described. .

Anal. Calc. for $C_{26}H_{28}N_2O_8 \cdot 0.45 H_2O$: C 61.89, H 5.77, N, 5.55

Found: C 61.91, H 5.75, N, 5.44.

MS (FAB+ion) m/z 497 (M+H)⁺

25 Example 6

4-[N-[2- α -Hydroxy-3- α -(4-benzoxazol-2-ylbenzyloxy)cyclohex-1-yl]- β -
carbamoyl]-3-hydroxy-3-carboxybutyric acid

The title compound is prepared as described in example 1 except that 1
N NaOH is used to hydrolyze the ester at room temperature. Upon completion
30 (TLC analysis) the solution is acidified and the resultant precipitate is collected
(filtration or centrifugation) and purified by washing with copious amounts of
water.

Anal. Calc. for $C_{26}H_{28}N_2O_9 \cdot 0.72 H_2O$: C 59.43, H 5.65, N 5.33

Found: C 59.43, H 5.66, N 5.25.

35

Example 7

(\pm)-4-[trans, trans-N-(3, 7, 11-trimethyl-2, 6, 10-dodecatrien-1-yl)carbamoyl]-3-
hydroxy-3-carboxybutyric acid

The title compound is prepared as described in example 1 except that LiOH (10 equiv.) is used to hydrolyze the ester. Upon completion (TLC analysis) the solution is acidified and extracted into ethyl acetate. The product is obtained upon crystallization with hexane.

5 Anal. Calc. for $C_{21}H_{33}NO_6$: C 63.78, H 8.41, N 3.54

Found: C 63.64, H 8.30, N 3.63.

Example 8

10 4-[3-Hydroxy-3-(4-(2-hydroxyquinolin-6-yl)phenyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

4-[3-Hydroxy-3-(4-(2-hydroxyquinolin-6-yl)phenyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid diethyl ester (75 mg, 0.14 mmol) is prepared in the manner described above from the product of Preparation 14 and treated
15 with 10 N NaOH (55 μ L, 0.55 mmol). After stirring overnight at room temperature, water is added to dissolve the precipitate. The resulting solution is stirred for an additional 24 hours then concentrated. The solid is collected, washed repeatedly with hot ethanol then dissolved in water and filtered to remove any remaining insoluble particles. The aqueous solution is lyophilized
20 and the product (40 mg, 43 %) obtained as the sodium salt.

Anal. Calc. for $C_{26}H_{24}N_2O_8Na_2 \cdot H_2O \cdot 3NaOH$: C 46.16, H 4.32, N 4.14

Found: C 46.06, H 4.20, N 3.88.

MS (FAB +ion) m/z 539 (M+H)

25 In a like manner by the methods described in Example 8 the following compounds are prepared:

Example 9

30 4-[2-[4-(Benzoxazol-2-yl)benzyloxymethyl]pyrrolidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 5.

Anal. Calc. for $C_{25}H_{24}N_2O_8Na_2 \cdot 0.75 H_2O$: C 55.61, H 4.26, N 5.19

Found: C 55.60, H 4.68, N 5.04.

35 Example 10

4-[3-Hydroxy-3[4-(2, 3-dihydrobenzo[1, 4]dioxin-6-yl)phenyl]piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 9.

Anal. Calc. for $C_{25}H_{25}NO_9Na_2 \cdot 1NaOH \cdot 1H_2O$: C 51.11, H 4.80, N 2.38

Found: C 51.06, H 4.80, N 2.54.

MS (FAB+ion) m/z 530 (M+H)⁺

5

Example 11

- 10 4-{3-Hydroxy-3-[4-(2-methoxyquinolin-6-yl)phenyl]piperidin-1-ylcarbonyl}-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 10.

Anal. Calc. for $C_{27}H_{26}N_2O_8Na_2 \cdot 2.425H_2O$: C 54.40, H 5.22, N 4.70

Found: C 54.39, H 5.01, N 4.40.

- 15 MS (FAB+ion) m/z 509 (M+H)⁺.

Example 12

- 20 4-{3-[4-(2-methoxyquinolin-6-yl)phenyl]-1, 2, 5, 6-tetrahydro-pyridylcarbonyl}-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 17.

MS (FAB+ion) m/z 535 (M+H)⁺.

Example 13

- 25 4-{3-(4-naphthalen-2-yl-phenyl)-1, 2, 5, 6-tetrahydropyridyl-carbonyl}-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 16.

MS (FAB+ion) m/z 504 (M+H)⁺.

Example 14

- 30 4-{3-(4-(6-Hydroxynaphth-2-yl)phenyl)-3-hydroxypiperidin-1-ylcarbonyl}-3-hydroxy-3-carboxybutanoic acid, trisodium salt

The title compound is prepared as described in Example 1 from the products of Preparation 13, except that 1 N NaOH is used to hydrolyze the intermediate diester. Upon concentration, the precipitate is collected (filtration or centrifugation) and purified by repeatedly washing with ethanol (hot if necessary) followed by ether. The product is dried under high vacuum.

35

Anal. Calc. for $C_{27}H_{24}NO_8Na_3 \cdot 2.0H_2O$: C 54.46, H 4.74, N 2.35

Found: C 54.56, H 4.81, N 2.26.

MS (FAB+ion) m/z 560 (M+H)⁺

- 5 In a like manner, by the methods described in example 14, the following compounds are prepared :

Example 15

4-[3-(4-(Benzoxazol-2-yl)phenyl)-1, 2, 5, 6-tetrahydropyridylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

- 10 From the product of Preparation 18.

Anal. Calc. for C₂₄H₂₀N₂O₇Na₂•0.9H₂O: C 56.45, H 4.30, N, 5.49

Found: C 56.46, H 4.11, N, 5.33.

MS (FAB+ion) m/z 495 (M+H)⁺.

- 15 Example 16

4-[N-[2- α -Hydroxy-3- α -(4-benzoxathiazol-2-ylbenzyloxy)cyclohex-1-yl]- β -carbamoyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

Anal. Calc. for C₂₆H₂₆N₂O₈SN₂•2.15H₂O: C 51.09, H 5.00, N, 4.58

Found: C 51.08, H 4.90, N, 4.51

- 20 MS (FAB+ion) m/z 573 (M+H)⁺.

Example 17

4-[3-(4-Benzoxazol-2-ylbenzyloxy)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxypentanoic acid, disodium salt

- 25 From the product of Preparation 2.

Anal. Calc. for C₂₅H₂₄N₂O₈Na₂•1.5 H₂O: C 54.25, H 4.92, N 5.06

Found: C 54.00, H 4.64, N 4.94.

Example 18

- 30 4-(N-Biphen-4-ylcarbamoyl)-3-hydroxy-3-carboxybutanoic acid, disodium salt

Anal. Calc. for C₁₈H₁₅NO₆Na₂•1.775 H₂O: C 51.56, H 4.46, N 3.34

Found: C 51.55, H 3.98, N 3.36.

MS (FAB+ion) m/z 388 (M+H)⁺.

Example 19

4-[3-(4-(Benzoxazol-2-yl)benzyloxymethyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 3.

5 Anal. Calc. for $C_{26}H_{26}N_2O_8Na_2 \cdot 1.425 H_2O$: C 55.16, H 5.14, N 4.95

Found: C 55.14, H 5.06, N 4.77

Example 20

4-[3-(4-(Benzoxazol-2-yl)benzyloxy)pyrrolidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

10 From the product of Preparation 4.

Anal. Calc. for $C_{24}H_{22}N_2O_8Na_2 \cdot 1.525 H_2O$: C 53.39, H 4.68, N 4.19

Found: C 53.38, H 4.61, N 5.32

15 Example 21

4-[3-Hydroxy-3-(4-benzoxazol-2-ylphenyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 8.

Anal. Calc. for $C_{24}H_{22}N_2O_8Na_2 \cdot 1.925 H_2O$: C 52.69, H 4.76, N 5.12

20 Found: C 52.68, H 4.36, N 4.87.

MS (FAB+ion) m/z 579 (M+H)⁺.

Example 22

3-[N-[1-(4-Benzoxazol-2-ylbenzyloxy)but-2-yl]carbamoyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

25 From the product of Preparation 4.

Anal. Calc. for $C_{24}H_{24}N_2O_8Na_2 \cdot 3.0H_2O$: C 50.71, H 5.32, N 4.93

Found: C 50.51, H 5.18, N 4.86.

MS (FAB+ion) m/z 515 (M+H)⁺.

30 Example 23

3-[N-[4-(Benzoxazol-2-yl)benzyl]carbamoyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

Anal. Calc. for $C_{20}H_{16}N_2O_7Na_2 \cdot 1.35H_2O$: C 51.48, H 4.04, N 6.00

Found: C 51.48, H 3.99, N 5.93.

35 MS (FAB+ion) m/z 443 (M+H)⁺.

Example 24

4-[3-Hydroxy-2-(3'-methoxybiphenyl-4-yl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 11.

5 Anal. Calc. for $C_{24}H_{25}NO_8Na_2 \cdot 1H_2O$: C 55.49, H 5.24, N 2.70

Found: C 55.42, H 4.95, N 2.55.

MS (FAB+ion) m/z 502 (M+H)⁺.

Example 25

10 4-[3-(Biphenyl-4-yl)-3-hydroxypiperidine-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid, disodium salt

From the product of Preparation 12.

Anal. Calc. for $C_{23}H_{23}NO_7Na_2 \cdot 1.3H_2O$: C 55.88, H 5.21, N 2.83

Found: C 55.86, H 5.13, N 2.85.

15 MS (FAB+ion) m/z 472 (M+H)⁺.

Examples 26A and B

4-[2- α -(4-Styrylphenyl)cyclohex-4-enyl- β -carbamoyl]-3-hydroxy-3-carboxybutyric acid, diastereomers A and B

20

6- α -(4-Styrylphenyl)cyclohexyl-4-enyl- β -amine (Preparation 6) is coupled to diethylcitrate as described in example 1. The resultant diesters are recrystallized from EtOAc/Hexane to give one diastereomeric pair of enantiomers in a greater than 90 % purity, characterized as the long retention time diastereomer (HPLC). The mother liquors are concentrated and purified by HPLC to isolate the second diastereomeric pair of enantiomers having a shorter retention time than the crystallized material.

25 The diastereomer with longer HPLC retention time is hydrolyzed with 1 N NaOH in ethanol/water (3:1). Upon completion (TLC analysis) the solution is acidified and the mixture saturated with NaCl then extracted with CH_2Cl_2 . The organic extracts are concentrated to give an oily solid which is triturated with Et₂O. The supernatant liquid is concentrated to give 4-[2-trans-(p- β -styrylphenyl) cyclohexyl-4-enylcarbamoyl]-3-hydroxy-3-carboxybutyric acid, diastereomer 26A.

35

Anal. Calc. for $C_{26}H_{27}NO_6 \cdot 1.4 H_2O$: C 65.78, H 6.33, N 2.94

Found: C 66.16, H 6.80, N 2.94

MS (FAB+ion) m/z 450 (M+H)⁺.

The diastereomer with shorter HPLC retention time is hydrolyzed as above and the di sodium salt of the acid is isolated by decantation of the supernatant liquid. Trituration with a mixture of diisopropyl ether and ethanol affords 4-[2-trans-(p- β -styrylphenyl)cyclohexyl-4-enylcarbamoyl]-3-hydroxy-3-

5 carboxybutyric acid as the disodium salt, diastereomer 26B.

Anal. Calc. for $C_{26}H_{25}NO_6Na_2 \cdot 2.3H_2O$: C 58.38, H 5.58, N 2.62

Found: C 57.77, H 5.06, N 2.54.

MS (FAB+ion) m/z 494 (M+H)⁺.

10

Example 27

3-(N-{2- α -[4-(Benzoxazol-2-yl)benzyloxy]cyclohexyl}- β -carbamoyl)-3-carboxybutanoic acid

A solution of 2- α -[4-(benzoxazol-2-yl)benzyloxy]-cyclohexyl- β -amine (220 mg, 0.68 mmol) in anhydrous CH_2Cl_2 (10 mL) is treated with tricarballic acid (0.131 g, 0.74 mmol), EDC (0.207 g, 1.08 mmol), HOBT (0.155 g, 1.15 mmol) and triethylamine (0.3 ml, 2.15 mmol) under argon. The resulting mixture is stirred overnight at room temperature then diluted with 100 ml CH_2Cl_2 and extracted with 1N HCl solution. The organic layer is separated, dried over MgSO₄, filtered, concentrated and purified by HPLC (10mm X 25cm Dynamax-60A 8 μ M C-18 column) ramping from 0-100% acetonitrile in water over 50 min. with a flow rate of 10 ml/min. After lyophilization, the title product (36 mg, 10 %) is obtained.

Anal. Calc. for $C_{25}H_{23}N_1O_7Na_2 \cdot 0.5H_2O$: C 63.79, H 5.97, N 5.72

Found: C 63.78, H 6.02, N 6.05.

25

MS (FAB+ion) m/z 481 (M+H).

Example 28

3-Hydroxy-3-[-N-[2-hydroxy-2-(4-naphthalen-2-yl-phenyl)prop-2-yl]carbamoyl]pentandioic acid, disodium salt

30

1-(3-Dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (0.833 g, 4.34 mmol) followed by 1-hydroxybenzotriazole hydrate (0.66 g, 4.35 mmol), 3-hydroxy-3,4-bis(ethoxycarbonyl)butanoic acid (1.08 g, 4.35 mmol) in THF (50 ml) and triethylamine is added to a stirred solution of 1-amino-2-(4-bromophenyl)propan-2-ol (Preparation 19, 1 g, 4.35 mmol) in THF (45 ml). The reaction mixture is stirred at ambient temperature for 18 hrs, diluted with CH_2Cl_2 and washed with saturated NaHCO₃ solution followed by saturated NaCl solution.

35

The organic layer is dried over MgSO_4 , concentrated and purified by flash chromatography (2 % $\text{MeOH}/\text{CH}_2\text{Cl}_2$) to give 1-[2-(4-bromophenyl)-2-hydroxypropyl]-3-hydroxy-2,5-dioxopyrrolidin-3-ylacetic acid, ethyl ester (0.5 g, 28 % yield); MS (FAB+ion) m/z 414 / 416 ($\text{M}+\text{H}$)⁺ and 4-[2-(4-bromophenyl)-2-hydroxypropylcarbamoyl]-3-hydroxy-3-methyl butyric acid ethyl ester (0.94 g, 50 % yield); MS (FAB+ion) m/z 460 / 462 ($\text{M}+\text{H}$)⁺.

Naphthyltrimethyl stannane (Preparation 20, 0.31 mmol, 0.091 g), tetrakis(triphenyl phosphine)Palladium(0) (15 mg, 13 mmol), and ethyl 1-[2-(4-bromophenyl)-2-hydroxypropyl]-3-hydroxy-2,5-dioxopyrrolidin-3-ylacetate (0.12 g, 0.26 mmol) in anhydrous DMF are heated at 95 °C under an inert atmosphere for 3.5 hr. The reaction mixture is partitioned between EtOAc and saturated NaCl solution. The organic phase is washed several times with further quantities of saturated NaCl solution, dried (Na_2SO_4) and concentrated. The residue is purified by flash chromatography (EtOAc/Hexane, 35 to 50%), to yield ethyl 1-[2-(4-naphthalen-2-yl-phenyl-2-hydroxypropyl)-3-hydroxy-2,5-dioxopyrrolidin-3-ylacetate (66 mg, 55 %).

The ester is hydrolyzed as described in example 14 to give of the title compound (65 mg, 51 %).

Anal. Calc. for $\text{C}_{25}\text{H}_{23}\text{N}_1\text{O}_7\text{Na}_2 \cdot 1.5\text{H}_2\text{O}$: C 57.47, H 5.02, N 2.68

Found: C 57.36, H 5.21, N 2.68.

MS (FAB+ion) m/z 496 ($\text{M}+\text{H}$)⁺.

Example 29

5-[2- α -[4-(Benzoxazol-2-yl)benzyloxy]cyclohex-1-yl- β -amino]-3-carboxypentanoic acid

A solution of DMSO (0.25 mL, 3.5 mmol) in 15 mL of THF is cooled to -78°C and treated with oxalyl chloride (0.27 mL, 3.1 mmol). After 10 minutes, a solution of 2, 2-diethoxy ethanol in THF is added. The reaction mixture is stirred for 15 minutes at -78 °C and treated with triethyl amine (1.88 mL, 13.5 mmol). The resulting solution is warmed to 0 °C. In a separate flask, diethoxy (diethyl succinyl) phosphine oxide (1.3 g, 4.19 mmol) in THF is added to 0 °C suspension of 60 % NaH (0.16 g, 4.05 mmol) in THF. After stirring for 1 hour at 0 °C, the resulting solution is added to the preformed aldehyde solution via a cannula. The reaction mixture is stirred for 2 hours and then poured into ether/water mixture. Aqueous layer is separated and further extracted with ether. Organic layers are combined, dried over MgSO_4 , and flash

chromatographed on silica gel with 8:2 hexane/ethyl acetate to yield diethyl 2-(2, 2-diethoxy ethenyl) succinate (0.6 g, 77 %).

Diethyl 2-(2, 2-diethoxy ethenyl) succinate (0.6 g, 2.1 mmol) is
5 hydrogenated under 45 psi of H₂ atmosphere for 1-1/2 days in 50 mL of EtOAc over 10 % Pd/C to yield diethyl 2-(2, 2-diethoxy ethyl) succinate (0.33 g, 55%).

Diethyl 2-(2, 2-diethoxy ethyl) succinate (0.33 g, 1.1 mmol) dissolved in
20 mL of THF is treated with 2 drops of concentrated HCl and stirred for 45
10 minutes at room temperature. The reaction mixture is diluted with 100 mL of ether, dried over MgSO₄, filtered, and concentrated to yield diethyl 2-(2-oxoethyl) succinate (0.23 g, 98 %).

A solution of acetic acid salt of 2- α -[4-(benzoxazol-2-yl)benzyloxy]-
15 cyclohexyl- β -amine (0.46 g, 1.11 mmol) and diethyl 2-(2-oxoethyl) succinate (0.24 g, 1.11 mmol) in methanol is treated with NaBH₃CN (0.07 g, 1.11 mmol) at room temperature for 4 hours. Removal of solvent followed by silica gel flash chromatography with 10 % MeOH in CH₂Cl₂ gives 140 mg (24 %) of the diethyl ester.

20

The diester is hydrolyzed by the method described in example 2 except the reaction mixture is acidified to pH 2 with HCl/EtOH solution and concentrated *in vacuo*. The title compound (30 mg, 24 %) is purified via HPLC (10mm X 25cm Dynamax-60A 8 μ M C 18 column) ramping from 20 to 80 %
25 CH₃CN in H₂O over 50 min. with a flow rate of 10 mL/min.

Anal. Calc. for C₂₆H₃₀N₂O₆•1.3H₂O: C 63.74, H 6.71 N, 5.72

Found: C 63.74, H 6.45, N, 5.91.

MS (FAB+ion) m/z 467 (M+H).

30 Example 30

3-(R)-(N-{2- α -[4-(Benzoxazol-2-yl)benzyloxy]cyclohexyl}- β -carbamoylaza)-3-carboxypropanoic acid

A solution of 2- α -[4-(Benzoxazol-2-yl)benzyloxy]-cyclohexyl- β -amine (400 mg, 1.24 mmol), triphosgene (123 mg, 0.41 mmol) and triethylamine (106
35 μ L, 4.35 mmol) in 15 mL CH₂Cl₂ is stirred at room temperature for 5 hours. Triethylamine (173 μ L, 1.24 mmol) and D-aspartic acid dimethyl ester hydrochloride (245 mg, 1.24 mmol) is added. The resulting mixture is heated to

40 °C and stirred overnight. The reaction mixture is washed with saturated sodium bicarbonate solution and the organic layer is dried over MgSO₄, filtered and concentrated. The crude material is purified by flash chromatography (1 % methanol/methylene chloride) to give the intermediate diester (490 mg, 77 %) as
5 a white solid.

Lithium hydroxide monohydrate (501 mg, 11.9 mmol) is added to a solution of the intermediate diester (490 mg, 0.96 mmol) in THF/methanol/water (9:3:3) and stirred overnight at room temperature. The reaction mixture is
10 concentrated and the contents partially dissolved in hot water (30 mL). After cooling, the solution is extracted with diethyl ether. The aqueous layer is partially concentrated and conc. HCl is added dropwise until the pH approximates 2. The acidic solution is cooled (about 5 °C) for 30 minutes. The crystallized product (215 mg, 46 %) is filtered, washed with water and dried on
15 the vacuum pump overnight.

Anal. Calc. for C₂₅H₂₇N₃O₇•0.5 H₂O: C 61.22, H 5.75, N 8.62

Found: C 61.27, H 5.71, N 8.62.

In a like manner by the method described in Example 30 the following
20 compounds are prepared using the corresponding amine:

Example 31

3-[N-[4-(Benzoxazol-2-yl)phenylmethyl]carbamoylaza]-3-carboxypropanoic acid

Anal. Calc. for C₁₉H₁₇N₃O₆•1.46H₂O: C 55.71, H 4.90, N 10.26

25 Found: C 55.70, H 4.61, N 10.05.

Example 32

3-(S)-(N-[2-α-[4-(Benzoxazol-2-yl)benzyloxy]cyclohexyl]-β-carbamoylaza)-3-carboxypropanoic acid

30 Anal. Calc. for C₂₅H₂₇N₃O₇: C 62.36, H 5.65, N 8.73

Found: C 62.08, H 5.71, N 8.74.

Example 33

35 3-(S)-[3-[4-(benzoxazol-2-yl)phenyl]-1, 2, 5, 6-tetrahydropyrid-1-yl]carbonylaza)-3-carboxypropanoic acid

From the product of Preparation 18.

Anal. Calc. for $C_{23}H_{21}N_3O_6 \cdot 0.5H_2O \cdot 0.4 EtOH$: C 61.70, H 5.27, N 9.07

Found: C 61.78, H 5.29, N 9.17.

Example 34

5 3-(R)-{3-[4-(benzoxazol-2-yl)phenyl]-1, 2, 5, 6-tetrahydropyrid-1-ylcarbonylaza}-3-carboxypropanoic acid

From the product of Preparation 18.

Anal. Calc. for $C_{23}H_{21}N_3O_6 \cdot 0.76 EtOH$: C 62.61, H 5.47, N 8.94

Found: C 62.35, H 5.51, N 8.93.

10

Example 35

3-(S)-{N-[2- α -(4-Styrylphenyl)cyclohex-4-enyl]- β -carbamoylaza}-3-carboxypropanoic acid

Anal. Calc. for $C_{25}H_{26}N_2O_5 \cdot 0.5 C_6H_{14}O$: C 69.26, H 6.85, N 5.77

15

Found: C 69.34, H 6.93, N 5.56.

MS (EI+ion) m/z 435 M⁺.

Various tests have been carried out to show the ability of the compounds of the present invention to exhibit pharmacological responses that can be correlated with activity in humans. These tests involve such factors as the effect of the compounds of Formula I to inhibit the synthesis of squalene. It has been found that compounds within the scope of this invention when tested using the following procedures show a marked activity for the inhibition of squalene synthase and hence are believed to be useful in the treatment of cholesterol-related disorders.

25

Squalene Synthase Inhibition Assay

The squalene synthase assay used is described by Amin et al. in "Bisphosphonates Used for the Treatment of Bone Disorders Inhibit Squalene Synthase and Cholesterol Biosynthesis," *Journal of Lipid Research*, **33**, 1657-1663 (1992).

35

I. Preparation of Assay Substances:

A) Test Solutions:

Test solutions are prepared fresh in 100 % DMSO or dH₂O. Subsequent dilutions are made in the same solvent. Compounds are tested initially at 1 μ M (final concentrations).

5 B) Assay Buffers:

Potassium Phosphate (50 mM,) pH 7.4, and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 50 mM) pH 7.4 stock buffers are prepared and stored at 4 °C until use.

10 C) Microsomal Enzyme Preparation:

Fresh livers from male Sprague-Dawley rats (Taconic Farms, Germantown, NY) weighing 150-200 g are collected after exsanguination. All subsequent procedures are performed at 4°C. The liver is homogenized in the assay buffer (50 mM, pH 7.4). Cellular fractions are separated as described by
15 Popjak, G. in "Enzymes of sterol biosynthesis in liver and intermediates of sterol biosynthesis," *Meth. Enzymol.* **15** 393-454 (1969). Microsomes are prepared by centrifugation (100,000 g) and then resuspended in the assay buffer. Microsomes are rehomogenized with a motor-driven Teflon pestle to yield a uniform suspension (~30 mg protein/ml), aliquoted, and stored at -80 °C until
20 use.

II. Squalene Synthase Assay

The procedure is a modification of those described by Popjack (*vide supra*) and Poulter et al. in "Squalene synthase. Inhibition by ammonium
25 analogues of carbocationic intermediates in the conversion of presqualene diphosphate to squalene" *J. Am. Chem. Soc.* **111**, 3734-3739 (1989). The assay is performed in 1 ml of 50 mM assay buffer, pH 7.4, containing 10 mM MgCl₂, 0.5 mM NADPH, microsomes (30 μ g protein), a test compound dissolved in distilled water or dimethylsulfoxide, and substrate [³H]FPP (0.5 μ M, 0.27
30 Ci/mmol) in a 16 x125 mm glass screw-cap tube. All components except [³H]FPP are preincubated for 10 min. at 37 °C. The reaction is initiated by the addition of [³H]FPP. After 10 min at 37 °C, the reaction is terminated by the addition of 1 ml 15 % KOH in ethanol. The tubes are incubated at 65 °C for 30 min. to solubilize proteins. The mixture is extracted with 5 ml petroleum ether
35 for 10 min. After freezing the lower aqueous phase, the organic phase is transferred to glass tubes containing 2 ml distilled water. After washing the lower aqueous phase is frozen and the petroleum ether phase is removed and






counted with 10 ml Ready Safe liquid scintillation cocktail using a Beckman LS-9000 scintillation counter. DPM values are adjusted against a blank (no enzyme).


- 5 The difference in radioactivity in the presence and absence of the test compound is used to determine the level of inhibition. The IC_{50} values are calculated using a linear regression program of Tallarida and Murray (1987). Tallarida, R.J. and Murray, R.B. *Manual of pharmacologic calculations with computer programs*. Springer-Verlag, 1987.

10

The following table shows examples of representative compounds of this invention and their test results as determined in the squalene synthase inhibition assay.

15

Table		HEPES buffer IC_{50}
Example 5		0.19 μ M
		10 μ M
Example 22		77 nM
Example 19		51 nM
Example 12		36 nM



Compounds within the scope of Formula I have been tested by the foregoing assay procedures and exhibit marked squalene synthase inhibition activity and are useful as hypocholesterolemic or hypolipidemic agents by virtue of their ability to inhibit the biosynthesis of cholesterol. Having such ability, the compounds are incorporated into pharmaceutically acceptable carriers and administered to a patient in need of such cholesterol biosynthesis inhibition. These pharmaceutical formulations contain at least one compound according to this invention.

10

Treatment with a combination of an HMG-CoA reductase inhibitor and a squalene synthase inhibitor would have a synergistic effect on inhibiting cholesterol biosynthesis. Inhibiting the squalene synthase enzyme and the HMG-CoA reductase enzyme at the same time would most closely resemble the physiological conditions of cholesterol homeostasis. A squalene synthase inhibitor could keep cellular concentrations of farnesyl diphosphate high enough for the synthesis of the small amounts of dolichol, ubiquinone, and the farnesylated proteins required by the cell. This would maintain some feedback regulation of the HMG-CoA reductase enzyme and allow smaller amounts of the HMG-CoA reductase inhibitor to be used.

20

Other combinations with a squalene synthase inhibitor which could have a synergistic effect for controlling undesirable cholesterol levels in the body include niacin, antihyperlipoproteinemic agents such as gemfibrozil, cholesterol absorption inhibitors, bile acid sequestrants, antioxidants and lipoxigenase inhibitors.

Compounds of the present invention which inhibit squalene synthase may also be of use in combating fungal infections in animals and humans. They may be useful in the treatment of variety of systemic infections and treating tropical infections. They may be also useful as prophylactic agents to prevent systemic and tropical fungal infections. Prevention of fungal overgrowth during antibiotic treatment may also be desirable in some disease syndromes.

Compounds may be tested under a spectrum of activity against a panel of representative yeasts, filamentous fungi and bacteria. The ability of compounds of the invention to inhibit the enzyme squalene synthase in fungi and bacteria may be demonstrated *in vitro* using (^{14}C)FPP as a substrate under assay conditions similar to those described by S. A. Biller et al. in *J. Medicinal Chemistry* **31**, 1869-1871 (1988), or Amin et al. *Journal of Lipid Research*, **33**, 1657-1663 (1992).

The *in vitro* evaluation of the anti-fungal activity of compounds of the invention can be performed by determining the minimum inhibitory concentration (MIC) which is the concentration of the test compound in a suitable medium at which growth of a particular microorganism fails to occur.

The compounds of the present invention can be administered to a mammalian host in a variety of forms adapted to the chosen route of administration, i.e., orally, or parenterally. Parenteral administration in this respect includes administration by the following routes: intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, transepithelially including transdermal, ophthalmic, sublingual and buccal; topically including ophthalmic, dermal, ocular, rectal and nasal inhalation via insufflation and aerosol and rectal systemic.

The active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic
5 administration, the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently
10 be between about 2 to about 6% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about about 1 and 1000 mg of active compound.

15 The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be
20 added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit.
25 For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens a preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and
30 substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

The active compound may also be administered parenterally or
35 intraperitoneally. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersion can also be prepared in

glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

5 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It may be stable under the conditions of manufacture and storage and must be
10 preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating
15 such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimersal, and the like. In many cases, it will be preferable to include isotonic agents, for
20 example, sugars or sodium chloride. Prolonged absorption of the injectable compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

 Sterile injectable solutions are prepared by incorporating the active
25 compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated
30 above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.


35 The therapeutic compounds of this invention may be administered to a mammal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and

chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.

- The physician will determine the dosage of the present therapeutic agents which will be most suitable for prophylaxis or treatment and it will vary with the form of administration and the particular compound chosen, and also, it will vary with the particular patient under treatment. He will generally wish to initiate treatment with small dosages by small increments until the optimum effect under the circumstances is reached. The therapeutic dosage will generally be from about 0.1 to about 1000 mg/day, and preferably from about 10 mg to about 100 mg/day, or from about 0.1 mg to about 50 mg/kg of body weight per day and preferably from about 0.1 to about 20 mg/kg of body weight per day and may be administered in several different dosage units. Higher dosages, on the order of about 2x to about 4x, may be required for oral administration.

WE CLAIM:




1. A compound of the formula:



where:

A is O, S, NR, SO, SO₂ or a bond;

B is (CRR)₁₋₂, O, S, NR, SO, SO₂, RC=CR, C≡C, O=C or a bond;



W is a bond, (CRR)_h, or NR;

R is hydrogen or alkyl;

R' and R'' are independently hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl or phenyl;

R' and R'' together may form a double bond;

R_1 and R_2 are independently hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl or phenyl;

5 R_3 , R_4 , R_5 and R_6 are independently hydrogen or alkyl;

R_7 is H, NRR or OH and when W is $(CRR)_h$ then R_7 is OH;

one of R_3 , R_4 , R_5 , R_6 or R_7 is OH;

10 Alk is bi- or tri- carbocycloalkane;

Ar I and Ar II are independently a mono- or di-aryl or heteroaryl;

15 a and b are independently 0-3;

a + b is 0-4;

d is 0-3;

20 a + b + d is 1-3;

e is 0-3;

f is 0-2;

25 g is 0-2;

h is 1-2;

30 m and n are independently 0-2;


x is 1-6;

y is 0-2;


35 x + y is 3-6; and

its stereoisomers, enantiomers, diastereoisomers and racemic mixtures; or a pharmaceutically acceptable salt thereof.


- 5 2. A compound according to Claim 1 of the formula:




- 10 3. A compound according to Claim 1 of the formula:




- 15 4. A compound according to Claim 1 of the formula:




- 20 5. A compound according to Claim 1 of the formula:




- 25 6. A compound according to Claim 1 of the formula:




- 5 7. A compound according to Claim 1 of the formula:




- 10 8. A compound according to Claim 1 of the formula:



- 15 9. A compound according to Claim 1 of the formula:




10. A compound according to Claim 2 of the formula:



where ArII is selected from phenyl, pyridyl, naphthyl, benzoxaxolyl, quinolinyl or benzothiazolyl.

5


11. A compound according to Claim 4 of the formula:



10 where ArII is selected from phenyl, pyridyl, naphthyl, benzoxaxolyl, quinolinyl or benzothiazolyl.

12. A compound according to Claim 6 of the formula:


15



where ArII is selected from phenyl, pyridyl, naphthyl, benzoxaxolyl, quinolinyl or benzothiazolyl.


20

13. A compound according to Claim 12 of the formula:




25

14. A compound according to Claim 12 of the formula:




15. A compound according to Claim 12 of the formula:

5




16. A compound according to Claim 12 of the formula:

10



17. A compound according to Claim 12 of the formula:

15



18. A compound according to claim 13 which is 4-[3-hydroxy-2-(3-methoxybiphenyl-4-yl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid or a pharmaceutically acceptable salt thereof.

20


19. A compound according to claim 14 which is 4-[3-hydroxy-3-(4-naphthalen-2-ylphenyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid or a pharmaceutically acceptable salt thereof.

25


20. A compound according to claim 16 which is 4-[3-(4-(benzoxazol-2-yl)benzyloxymethyl)piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid
 5 or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 15 which is 4-[3-hydroxy-3-[4-(2-methoxyquinolin-6-yl)phenyl]piperidin-1-ylcarbonyl]-3-hydroxy-3-carboxybutanoic acid or a pharmaceutically acceptable salt thereof.
 10

22. A compound of Claim 1 of the formula:



23. A compound of Claim 22 of the formula:



24. A method of lowering or maintaining reduced cholesterol levels in a patient requiring such treatment which comprises administering to such patient a
 25 squalene synthase inhibitor effective amount of a compound of the formula according to Claim 1.

25. A method for inhibiting cholesterol biosynthesis which comprises
 30 administering to a patient in need of such inhibition a squalene synthase inhibiting effective amount of a compound according to Claim 1.

26. A method according to Claim 25 where the patient is in need of a hypocholesterolemic or hypolipidemic agent.

5

27. A method according to Claim 26 for treating atherosclerosis.

28. A pharmaceutical composition comprising a squalene synthase inhibitor
10 effective amount of a compound according to Claim 1 in admixture with a pharmaceutical carrier.

29. A pharmaceutical composition according to Claim 28 which further
15 includes an HMG CoA reductase inhibitor.

1/1




Figure 1 Cholesterol Biosynthetic Pathway

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/15364

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/217, 530; 546/175, 193, 197, 242; 540/450, 484; 514/183, 212, 314, 317, 318, 321, 423

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,E	US, A, 5,492,915 (DEREU ET AL) 20 February 1996; see entire patent.	1-29
A	US, A, 5,164,371 (EDWARDS ET AL) 17 November 1992; see entire patent , especially the claims.	1-29
A	US, A, 5,070,196 (MASAKI ET AL) 03 December 1991; see entire document.	1-29
A	US, A, 4,920,130 (HUANG ET AL) 24 April 1990; see entire document.	1-29

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O documents referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
16 JANUARY 1996

Date of mailing of the international search report

26 MAR 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

DAVID B. SPRINGER

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235

28X2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/15364

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C07D 207/04, 211/32, 223/02, 225/02, 401/12, 413/12; A61K 31/33, 31/40, 31/41, 31/42, 31/47, 31/553, 31/445

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

548/217, 530; 546/175, 193, 197, 242; 540/450, 484; 514/183, 212, 314, 317, 318, 321, 423

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

~~/~~ Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)